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a b s t r a c t
The equine herpesvirus type 1 (EHV-1) open reading frame 34 (ORF34) is predicted to encode a
polypeptide of 161 amino acids. We show that an ORF34 deletion mutant exhibited a signiﬁcant growth
defect in equine peripheral blood mononuclear cells taken directly ex vivo during early but not late times
of infection. ORF34 protein (pORF34)-speciﬁc antibodies speciﬁcally reacted with a 28-kDa early
polypeptide present in the cytosol of infected cells. From 10 h post infection, multiple smaller
pORF34-speciﬁc protein moieties were detected indicating that expression of a late viral gene product(s)
caused pORF34 degradation. Proteasome inhibitors blocked pORF34 degradation as did treatment of
infected cells with a ubiquitin-activating enzyme (E1) inhibitor. Finally, kinetic studies showed that pORF34
is modiﬁed by addition of multiple copies of ubiquitin. Taken together, our ﬁndings suggest that the
ubiquitin proteasome pathway is required for pORF34 degradation that may modulate protein activity in
the course of infection.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Equine herpesvirus type 1 (EHV-1) is a member of the genus
Varicellovirus within the Alphaherpesvirinae subfamily (Davison
et al., 2009) and remains one of the most common viral infections
of horses causing respiratory, neurological and abortigenic disease
(Allen et al., 2004; Allen and Yeargan, 1987; Carroll and Westbury,
1985; Crabb and Studdert, 1995). Its genome is a double-stranded
DNA of 150-kbp in length (Nugent et al., 2006; O’Callaghan and
Osterrieder, 2008) with 80 identiﬁed open reading frames (ORFs)
that encode 76 unique genes and 4 that are duplicated in the
inverted repeat regions (Davison et al., 2009; Telford et al., 1992).
Viral replication requires a coordinated gene expression program
in which immediate early (IE) progresses to early (E) and ﬁnally
late (L) gene expression (Caughman et al., 1985; Gray et al., 1987).
Alphaherpesvirus genomes exhibit a generally colinear gene
arrangement and most of the genes are conserved among the
different members of the subfamily. Exceptions to this rule apply
to six of the 76 unique genes in EHV-1, namely ORF 1, 2, 3, 34, 59
and 67, which do not have known homologues in human herpes
simplex virus (HSV) (Telford et al., 1992). The ORF1, 2, 3, 59 and 67
gene products of EHV-1 have already been characterized pre-
viously (Ma et al., 2012; Soboll Hussey et al., 2011; Ahn et al., 2011;
Osterrieder et al., 1996; Said and Osterrieder, 2013). EHV-1 ORF34
and its product have not yet been characterized. The gene is
located in the unique-long region of the genome and predicted to
encode a protein with a calculated molecular mass of approx.
18,000 (Telford et al., 1992). Alignment by CLUSTAL of the amino
acid sequence of EHV-1pORF34 to its counterparts of EHV-4
(pORF34) and VZV (pORF32) revealed that EHV-1pORF34 has an
overall amino acid identity of 72% with its EHV-4 counterpart but
only 24% with VZV pORF32 (Fig. 1).
Herpesvirus replication requires extensive modulation of many
cellular pathways, among them the ubiquitin–proteasome path-
way. For example, the HSV-1 transactivator ICP0 has been shown
to utilize the proteasome-dependent pathway to induce cellular
protein degradation and steer viral replication (Boutell et al., 2002;
Everett, 2000; Kalejta and Shenk, 2003). The ubiquitin–protea-
some system regulates important cellular functions including the
cell cycle, antigen presentation, signal transduction and gene
transcription as well as DNA repair (Pickart and Fushman, 2004;
Prosch et al., 2003). The activation of ubiquitin by the E1 ubiquitin-
activating enzyme, followed by the covalent addition of ubiquitin
onto substrates by a number of ubiquitin ligases results in either
protein degradation or modiﬁcation of protein function (Pickart
and Fushman, 2004; Prosch et al., 2003). Proteins tagged for
degradation are targeted to the 26S proteasome, a multimeric
protease consisting of a 20S catalytic core capped at both ends by
19S regulatory subunits (Demartino and Gillette, 2007; Forster and
Hill, 2003). Cells utilize the proteasomal pathway to tune protein
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levels and efﬁciently degrade aberrantly folded proteins to ensure
cellular homeostasis.
Considerable effort has been devoted to understanding the
replication of EHV-1 and the function of its gene products in order
to generate information that may be useful in the rational design
of better vaccines. To date, the product of EHV-1 ORF34 is a viral
protein with unknown function. The goals of this study were to
identify and characterize the EHV-1 ORF34 gene product and to
investigate whether the ORF34 protein (pORF34) has a role in virus
replication. We, therefore, generated and characterized an EHV-1
Ab4 mutant with a deletion of ORF34 and report that EHV-1
ORF34 is expressed with early kinetics and its product is localized
within the cytosol of infected cells. In addition, pORF34 is
degraded in the proteasome following ubiquitination, a process
that requires a late viral gene product(s). Moreover, EHV-1 Ab4
ORF34 expression replicated with reduced efﬁciency in vitro at
early but not late stages of infection.
Results
Generation of mutant viruses
To generate EHV-1 Ab4 lacking ORF34 (rAb4Δ34), en passant
mutagenesis was employed (Fig. 2A) (Tischer et al., 2006). During
the ﬁrst recombination event, the insertion into pAb4 of the
ampliﬁed aphA1 gene instead of ORF34 gene resulted in
kanamycin-resistant intermediates that exhibited the expected
changes as reﬂected in the XbaI restriction enzyme pattern by
the presence of a fragment of 9749 bp in size compared to the
8719 bp fragment present in pAb4 (Fig. 2B). Positive clones were
subjected to the second round of Red recombination to obtain the
ﬁnal construct after excision of the aphAI gene (Tischer et al.,
2006). DNA from colonies that were kanamycin-sensitive but
chloramphenicol-resistant was extracted and again checked by
RFLP analysis after digestion with XbaI. The second recombination
event resulted in the reduction in size of the 9749 bp XbaI
fragment to 8236 bp (Fig. 2B). The results of the RFLP analysis
were conﬁrmed by Southern blotting, which revealed that only the
XbaI band containing ORF34 sequences in pAb4 and the pAb4Δ34R
revertant clone, but not that in pAb4Δ34, was reactive with the
ORF34-speciﬁc probe (data not shown). Nucleotide sequencing
further conﬁrmed the deletion of ORF34 in the mutant pAb4Δ34.
Next, a virus with an HA-tag at the C-terminus of ORF34 was
generated using the same methodology. PCR analysis showed that
HA tag sequences in pAb4_34-HA were correctly inserted, which
was conﬁrmed by nucleotide sequencing (data not shown) and
RFLP (Fig. 2). In the pAb4_34-HA intermediate, the 8719 bp XbaI
fragment present in pAb4 increased in size to 9724 bp. After the
second recombination and removal of the aphA1 gene, a reduction
in size of the 9724 bp XbaI fragment to 8746 bp was evident
(Fig. 2C). The appropriate revertant from pAb4Δ34, in which the
original sequences were restored, was also generated using en
passant recombination (Fig. 2).
In vitro characterization of the ORF34 protein
To characterize the ORF34 product, recombinant EHV-1 with an
HA tag at the C-terminus of ORF34 (rAb4_34-HA) as well as
a polyclonal anti-pORF34 antibody targeting the protein's
N-terminus (N-pORF34) were used. To verify the speciﬁcity of
the anti-HA MAb in the detection of pORF34 expression, RK13 cells
were transfected with expression vectors harboring either ORF34
(pcDNA_34) or ORF34 tagged with HA sequences (pcDNA_34-HA).
Also, lysates of RK13 cells infected with parental rAb4 or rAb4_34-
HA were included in the assay. Cell lysates were harvested from
transfected and infected cells and subjected to Western blot
analysis using the anti-HA MAb and the N-pORF34 antibody.
In transfected cells, the anti-HA antibody detected a 28-kDa band
corresponding to pORF34 in pcDNA_34-HA-transfected cells
(Fig. 3A) but not in lysates of cells transfected with pcDNA (vector
control) or pcDNA_34. The anti-HA antibody also detected a
pORF34-speciﬁc band of the same size in rAb4_34-HA-infected
cells at 5 h p.i., while multiple additional bands of 17- to 28-kDa
were also detected at 24 h p.i. (Fig. 3B). Expression of pORF34 was
not detected in the parental virus with the HA antibody (Fig. 3B).
In contrast, the N-pORF34 antibody was able to detect only a
single 28-kDa band in lysates of parental virus at 5 and 24 h p.i.,
but did not react with the additional bands of 17- to 28-kDa at
24 h p.i. (Fig. 3C). We concluded from the results that both the
anti-HA antibody and the pORF34-speciﬁc peptide antibody were
able to detect a 28-kDa pORF34-speciﬁc band and did not exhibit
any cross-reactivity with other viral or cellular proteins.
pORF34 is expressed with early kinetics and is not
post-translationally modiﬁed by phosphorylation or glycosylation
To determine the kinetics of ORF34 expression, Western blot
analysis was performed with lysates of infected cells harvested at
different time points in the presence or absence of PAA. Expression
of β-actin and gM, a late EHV-1 protein, was also assessed to
control efﬁciency of PAA treatment. The HA-tagged pORF34 was
detected as early as 1 h p.i. at signiﬁcant levels, which was not
affected by PAA treatment, in contrast to gM expression (Fig. 4A).
To clearly distinguish between the IE or E phase of gene expres-
sion, NBL6 cells were either mock-infected or infected with
rAb4_34-HA in the presence of CX for 5 h followed by extensive
washing and addition of Act-D (CX/Act-D), and treated cells were
Fig. 1. CLUSTAL alignment of the EHV-1 pORF34 with its orthologues of EHV-4 and VZV. Amino acid residues that are conserved in the three proteins are shown in black
boxes. The EHV-1 pORF34 has 72% and 24% overall amino acid identity with its orthologues of EHV-4 and VZV, respectively.
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subjected to Western blot analysis (Fig. 4B). pORF34 was not
detected after treatment of cells with CX/Act-D (Fig. 4B). Taken
together, we concluded that pORF34 is expressed with early
kinetics in infected cells. It was previously reported that VZV
pORF32 was modiﬁed by phosphorylation (Reddy et al., 1998).
To test the hypothesis that the EHV-1 orthologue is also modiﬁed
by phosphorylation, rAb4_34-HA-infected cell lysates were treated
with λ-PPase. We were unable to demonstrate any change in
electrophoretic mobility of any of the pORF34 moieties in the
presence of the enzyme (data not shown). To determine whether
EHV-1 protein kinases, encoded by US3 (ORF69) and UL13 (ORF49)
might be associated with the phosphorylation of pORF34, NBL6
cells were infected with the respective protein kinase mutants
(Ma et al., 2012). Multiple forms of pORF34 were still detected by
Western blot analyses in cells after infection with either of the
mutants (data not shown). Furthermore, to address pORF34
modiﬁcation by glycosylation, rAb4-infected cell lysates were
treated with either PNGaseF or EndoH. Using anti-pORF34
Fig. 2. Construction of EHV-1 lacking ORF34 (rAb4Δ34) or expressing epitope-tagged pORF34 (rAb4_34-HA). (A) Schematic diagram of the procedures used to delete the
ORF34 gene from pAb4 and to insert an HA tag at the pORF34 carboxy-terminus. Schematic representation of the genomic organization and the XbaI restriction map of
(pAb4) is given. The two unique segments (UL and US), and the terminal and internal repeat sequences (TRS and IRS) are shown. Two-step en passant mutagenesis was
employed for manipulation of pAb4 and for generation of rAb4Δ34 and rAb4_34-HA. (B) Identiﬁcation of pAb4Δ34 by RFLP. Puriﬁed DNA from pAb4 (lane 1), the kanamycin-
resistant intermediate (lane 2), the ﬁnal constructs pAb4Δ34 (lane 3) and pAb4Δ34R (lane 4) were digested with XbaI and separated by 0.8% agarose gel electrophoresis.
(C) Identiﬁcation of pAb4_34-HA by RFLP. Puriﬁed DNA from pAb4 (lane 1), the kanamycin-resistant intermediate (lane 2), the ﬁnal mutant pAb4_34-HA (lane 3) and
pAb4_34-HAR (lane 4) were digested with XbaI and separated by 0.8% agarose gel electrophoresis. GeneRuler 1 kb Plus DNA Ladder (Thermo Scientiﬁc) was used for
determination of DNA fragment sizes and was loaded in lane M.
Fig. 3. Characterization of pORF34 expression in transfected or infected cells. (A) RK13 cells were transfected with either pcDNA, pcDNA_34 or pcDNA_34-HA. A 28-kDa band
was detected in cell lysates transfected with pcDNA_34-HA but not in those pcDNA and pcDNA_34. Cells were infected either with parental rAb4 or rAb4_34-HA (B) or
parental rAb4 virus (C). At different times after infection (5 and 24 h p.i.), cell lysates were prepared and subjected to Western blot analysis. Anti-HA antibody or anti-pORF34
peptide antibody were used to detect pORF34 expression in (B) and (C), respectively. Identical concentrations of protein lysates were separated in each lane of an SDS-12%
polyacrylamide gel. The PageRulerTM Prestained protein ladder (Thermo Scientiﬁc) was used for determination of protein sizes.
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antibody targeting the protein's C-terminus (C-pORF34), we were
unable to detect any such modiﬁcations of pORF34 (Fig. 4C, left
panel). Expression of gB was used as a control for the efﬁciency of
PNGaseF or EndoH treatment (Fig. 4C, right panel). Taken together,
we concluded from our results that pORF34 is not posttransla-
tionally modiﬁed by glycosylation or phosphorylation.
pORF34 degradation is time-dependent
We had observed that multiple pORF34-speciﬁc bands were
detectable at later times after infection with the anti-HA antibody
that targeted the HA tag inserted at the C-terminus of the protein
in the rAb4_34-HA virus. However, only the full-length 28-kDa
band was detected with the anti-N-pORF34 antibody in rAb4 or
rAb4_34-HA at all times p.i. These results strongly suggested the
protein may undergo degradation. In order to assess the rate of the
presumed pORF34 degradation, RK13 cells were infected with
rAb4_34-HA virus. Infected cells were harvested at various times
p.i. (1, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24) and analyzed by
immunoblot. We observed only one speciﬁc band of 28-KDa for
pORF34 from 1 to 10 h p.i. At later times after infection, however,
additional bands with apparent molecular masses ranging
between 17- and 28-kDa appeared (Fig. 4A). Moreover, after
treatment of infected cells with PAA at 16 and 24 h p.i., only the
original 28-kDa pORF34-speciﬁc band was detected (Fig. 4A).
Overall, our ﬁndings suggested that expression of a late viral
protein(s) has a direct or indirect role in the appearance of
multiple pORF34 species.
pORF34 undergoes amino-terminal degradation
To determine whether EHV-1 ORF34 protein indeed undergoes
(amino-terminal) degradation, RK13 cells were either mock-infected
or infected with rAb4 or rAb4_34-HA. Cell lysates were harvested at
24 h p.i. from non-infected and infected cells and subjected toWestern
blot analysis using anti-HA MAb and antibodies targeting the N- and
C-terminus of pORF34. All of the antibodies speciﬁcally reacted with a
band of approximately 28-kDa in lysates of infected cells (Fig. 5).
However, reactivity of the band was weaker in the case of the anti-C-
pORF34 antibody in rAb4_34-HA-infected cell lysates (Fig. 5B).
Furthermore, the anti-HA MAb and the polyclonal antibody targeting
the C-terminus of pORF34 reacted with multiple smaller bands at later
times p.i. In contrast, those smaller bands were not reactive with anti-
N-pORF34 antibody in cells infected cells with either rAb4_34-HA or
rAb4 (Fig. 5C). We concluded from these observations that the ORF34
protein undergoes degradation that is initiated at its N-terminus.
Degradation of pORF34 occurs through the ubiquitin/proteasome
pathway
To examine the effect of the proteasomal degradation pathway
on pORF34 processing, RK13 cells were either mock-infected or
infected with rAb4_34-HA for 1 h to allow for virus adsorption.
After adsorption, cells were incubated with fresh medium with or
without lactacystin, a proteasome inhibitor, for an additional 24 h.
Western blot analysis of cell lysates revealed the presence of a
28-kDa band in cells treated with lactacystin, while additional
bands of 17- to 28-kDa were observed in non-treated cells,
consistent with our earlier ﬁndings (Fig. 6A). We concluded that
pORF34 is degraded through the proteasomal pathway.
In order to address whether pORF34 degradation through the
proteasome was dependent on ubiquitination, RK13 cells were trans-
fected with a 6XHis-tagged ubiquitin expression plasmid. At 24 h after
transfection, cells were infected with the rAb4_34-HA virus for 24 h.
Then, cell lysates were subjected to immunoprecipitation using the
anti-HA or -His MAb on the same lysates. Coupling of ubiquitin to
pORF34 was detected by reciprocal immunoblot analysis with anti-HA
or anti-His antibodies, respectively. As suggested by the presence of
multiple bands, pORF34 was modiﬁed by addition of multiple copies
of ubiquitin (Fig. 6B). To conﬁrm these results, RK13 cells were mock-
infected or infected with rAb4_34-HA for 1 h followed by treatment
with the E1 ligase inhibitor Pyr-41 for 24 h. Western blot analysis of
Pyr-41-treated cells indicated that the pORF34-speciﬁc band was
reduced in size but no degradation products were identiﬁed even at
late times after infection (Fig. 6C).
Taken together, our results showed that pORF34 is ubiquiti-
nated at later times after infection and targeted for degradation by
the proteasome.
To address the extent of covalent ligation of ubiquitin mole-
cules to pORF34, the viral protein was precipitated from cells
infected with either rAb4 parental or rAb4_34HA virus using an
Fig. 4. pORF34 is expressed with early kinetics and is not glycosylated.
(A) Expression of pORF34 in the presence or absence of PAA was determined for
each time point in panel A by Western blotting. Proteins were extracted from RK13
cells infected with rAb4_34-HA and an anti-HA MAb was used for detection. A 28-
kDa band was detected at 1 to 12 h p.i., as well as 16 and 24 h p.i. in the presence of
PAA. Bands with apparent molecular weights between 17- and 28-kDa were
detected at 12, 16, and 24 h p.i. in the absence of PAA. Expression of gM and
β-actin was determined as controls. (B) To differentiate whether pORF34 is an early
or immediate early protein, lysates from mock-infected cells or cells infected with
rAb4_34HA in the presence or absence of CX/Act-D were prepared and analyzed by
immunoblotting. A band of 28-kDa in size was detected in the presence of PAA
(Lane 4), and the 17-to 28-kDa moieties were detected in the absence of PAA.
(C) RK13 cells were either mock-infected or infected with rAb4 virus. Cell lysates
treated with PNGaseF or EndoH (BioLabs) for 3 h at 37 1C were analyzed by
Western blotting. Expression of gB, a glycosylated protein, was used as control for
the efﬁciency of PNGaseF and EndoH treatment. The PageRulerTM Prestained
protein ladder (Thermo Scientiﬁc) was used for determination of protein molecular
masses.
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anti-mono- and -poly-ubiquitin MAb. Then, immunoprecipitates
were examined by Western blotting, using the anti-HA and anti-C-
pORF34 antibody, respectively. Multiple pORF34-speciﬁc bands
were detected in the ubiquitin-speciﬁc precipitates in cells
infected with rAb4 parental and rAb4_34HA, while those bands
were absent from precipitates of mock-infected cells (Fig. 7A).
To determine the kinetics of pORF34 ubiquitination and
whether degradation is coincident with covalent addition of
polyubiquitin to the polypeptide, RK13 cells were infected with
rAb4 virus. Infected cells were harvested at different times p.i.
(2, 5, 10, 12 and 24). Anti-ubiquitin antibody was used to
precipitate ubiquitinated pORF34 and precipitated proteins were
analyzed as described earlier. We observed multiple ubiquitin-
containing bands using the pORF34-speciﬁc antibody starting at
12 h p.i. and lasting throughout the observation period (Fig. 7B).
Our ﬁndings, therefore, suggest that EHV-1 pORF34 is ubiquitiated
and that its degradation starts at a time when covalent attachment
of multiple copies of ubiquitin to pORF34 can be detected.
pORF34 is located in the cytoplasm of infected cells
In order to determine the subcellular localization of pORF34,
NBL6 cells infected with rAb4, rAb4_34-HA or mutant rAb4Δ34
were analyzed by indirect IF using anti-HA MAb or the anti-
pORF34 peptide antibody. Both antibodies revealed localization of
the ORF34 protein in the cytosol of cells infected with rAb4_34-HA
or parental rAb4 (Fig. 8A and B). As expected, the anti-HA MAb did
not detect pORF34 in cells infected with either parental EHV-1
lacking the HA tag or the rAb4Δ34 mutant (Fig. 8A). To conﬁrm the
localization of pORF34, cytoplasmic and nuclear fractions were
obtained from NBL6 cells infected with rAb4_34-HA and subjected
to Western blot analysis using the anti-HA MAb. These experi-
ments corroborated the ﬁndings of the IF analyses and showed
cytoplasmic localization of pORF34 (Fig. 8C).
Growth properties of ORF34-negative viruses in cultured cells
To determine whether pORF34 is essential for EHV-1 replica-
tion in vitro, equine NBL6 cells were infected with either parental,
mutant rAb4Δ34 or revertant virus, and plaques sizes were
determined. The results showed that the rAb4Δ34 was able to
grow on NBL6 cells with average plaque sizes that were not
signiﬁcantly (p¼0.29 and p¼0.34) different from those observed
after infection with parental or revertant viruses (Fig. 9A). We
concluded from the results that deletion of ORF34 is not required
for efﬁcient growth of EHV-1 in cultured ﬁbroblasts. When mutant
virus replication was evaluated by single-step growth kinetics,
extracellular and cell-associated virus titers of rAb4Δ34 virus were
determined at different time points. The EHV-1 ORF34 deletion
mutant grew with titers lower than parental and revertant viruses
at early times of infection (until 10 h p.i.). Starting from 12 h p.i.,
however, titers of mutant as well as parental and revertant virus
were virtually identical (Fig. 9B). These ﬁndings suggest that the
ORF34 protein is required for optimal replication of EHV-1 in
cultured cells at early times of infection.
To evaluate whether deletion of ORF34 impairs virus replica-
tion in a compartment important for EHV-1 replication and
pathogenesis in vivo, virus genome copies in equine PBMC infected
with either rAb4Δ34 virus, parental or revertant viruses were
determined by qPCR at 5 and 24 h p.i. All tested viruses were
capable of infecting PBMC with similar efﬁciencies (data not
shown). Signiﬁcant differences in viral genome copies were
detected at 5 but not at 24 h p.i. in that an approximately 7-fold
reduction in rAb4Δ34-infected PBMC was recorded at that time
point (Fig. 10). We concluded from our result that the ORF34
protein is required for optimal replication efﬁciency in equine
PBMC at early stages of infection.
Discussion
The ORF34 product of EHV-1 was the focus of this study.
Positional homologues to EHV-1 ORF34 have been identiﬁed in
EHV-4 gene 34 (Telford et al., 1998) and VZV gene 32 (Reddy et al.,
1998), but no homologous ORF was identiﬁed members of the
Simplexvirus genus (McGeoch et al., 1988, 1991). The predicted VZV
ORF32 and EHV-1/-4 ORF34 products are similar in length and
have low isoelectric points (3.9 to 4.8), because at least 15% of each
of the proteins is comprised of acidic amino acids. The VZV ORF32
protein has 24% overall amino acid identity with its EHV-1 and 72%
Fig. 5. Degradation of pORF34. To determine degradation of pORF34, RK13 cells were mock-infected or infected with either rAb4_34-HA or rAb4. Cell lysates were collected
24 h p.i. and then analyzed by Western blotting using anti-HA MAb (A) or anti-ORF34 peptide antibodies (B and C). All used antibodies reacted with a band of 28-kDa in cells
infected with rAb4 and rAb4_34-HA. The 17-to 28-kDa bands were detected with anti-HA MAb and anti-C-pORF34 (panels A and B) antibodies, but were not detected with
anti-N-pORF34 antibody (C). Prestained protein ladder (Thermo Scientiﬁc) was used for determination of protein molecular masses.
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amino acid identity with the EHV-4 orthologue (48). Moreover, the
three proteins are hydrophilic and none is predicted to be inserted
into membranes.
For functional analysis of EHV-1 pORF34, kinetic studies of
protein expression were conducted. Our data show that pORF34
expression started at 1 h p.i. and was not affected by PAA,
indicating that pORF34 is an early viral protein. Our ﬁndings are
in agreement with previous results showing that the VZV ORF32
protein is also expressed at early times after infection (Reddy et al.,
1998). pORF34 (with the inserted HA epitope) is a protein with a
molecular weight of 28-kDa in transfected and infected cells. Using
anti-pORF34 antibodies targeting N- or C-terminal sequences of
the protein, we detected a band with the same apparent molecular
mass of 28-kDa. This apparent mass is larger than that predicted
based on the sequence of the protein (18-kDa). Additional immu-
noblot analyses of pORF34 utilizing the anti-HA MAb and the anti-
peptide antibody targeting the protein's C-terminus allowed
speciﬁc detection of at least four bands ranging in molecular
weight from 17- to 28-kDa later in infection. Notably, these lower
molecular mass bands were detectable using the antibody target-
ing the C-terminus of pORF34 but we failed to detect the additional
bands using the pORF34-speciﬁc antibody that was raised to a peptide
located at the extreme N-terminus of the protein. Although we were
able to detect the 28-kDa moiety using the anti-C-pORF34 antibody in
cells infected with rAb4_34HA, we were not able to detect the
additional (degradation) bands ranging from 17- to 28-kDa. This is
an unexpected result, which offers room for speculation. We can think
of two possible explanations, which both have to do with the insertion
of the HA epitope and addition of 9 amino acids (YPYDVPDYA) at the
C-terminus of pORF34. This addition may indeed have an effect on the
Fig. 6. pORF34 protein degradation is via the ubiquitin/proteasome pathway.
(A) A proteasome inhibitor (lactacystin, 10 mM) was added to cells infected with
rAb4_34-HA. The drug was left on the cells for 24 h at 37 1C. Treated cells were then
collected and analyzed by Western blotting. Bands with molecular weights of 28-
kDa or 17- to 28-kDa were detected with the anti-HA antibody in the presence and
absence of lactacystine, respectively. (B) To investigate whether pORF34 is
ubiquitinated, RK13 cells were mock-infected, infected with rAb4_34-HA or
transfected with pMT107 and then infected with Ab4_34-HA. Cell lysates were
subjected to immunoprecipitation using the anti-HA (right panel) or anti-His MAbs
(left panel). Then, pORF34 ubiquitination was detected by Western blot using an
anti-HA (left panel) or an anti-His (right panel) antibody. Bands of 28- and 36-kDa
were detected with the anti-HA and anti-His antibody only in lysates of cells
transfected with pMT107 and infected with Ab4_34-HA. (C) To determine whether
proteasomal degradation of pORF34 is ubiquitin-dependent, RK13 cells infected
with rAb4_34-HA were treated with the E1 inhibitor (Pyr-41 at 25 mM) prior to and
after infection, then the treated cells were harvested and analyzed by Western
blotting. Prestained protein ladder (Thermo Scientiﬁc) was used for determination
of protein molecular masses.
Fig. 7. Covalent attachment of ubiquitin to pORF34. (A) RK13 cells were either
mock-infected (lanes 1 and 3), infected with rAb4_34HA (lane 2) or Ab4 parental
virus (lane 4). Immunoprecipitation using anti-ubiquitin MAbs was performed and
shown in the right and left panel, respectively. Samples were analyzed by Western
blotting using anti-HA and anti-C-pORF34 antibody in the left and right panel,
respectively. (B) Kinetics of ubiquitination of pORF34. Cells infected with rAb4 virus
were harvested at 2, 5, 10, 12 and 24 h p.i. and treated with anti-Ub antibodies as
described in (A). Precipitated proteins were subjected to SDS-12%–PAGE and
analyzed by immunoblotting with anti-C-pORF34 peptide antibody. Prestained
protein ladder (Thermo Scientiﬁc) was used for determination of protein molecular
masses.
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degradation process by increasing stability and reduced degradation
that can only be visualized with the highly afﬁne HA antibody. The
other explanation that we favor is that addition of the epitope may
interfere with binding of the anti-C-pORF34 antibody. Based on the
data and the differential banding patterns detected with the anti-HA
MAb and the pORF34-speciﬁc antibodies raised against peptides at the
N- and C-terminus, we currently conclude that pORF34 is degraded
sequentially from its amino-terminus.
We had originally surmised that the different bands may
represent degradation products or different forms of the proteins
due to posttranslational modiﬁcations. Phosphorylation is one of
common posttranslational modiﬁcation that regulates the herpes-
virus protein function (McDowell et al., 2013; Oster et al., 2008;
Reddy et al., 1998). We tested whether phosphorylation is respon-
sible for the observed effect on EHV-1 pORF34 based on the fact
that the VZV orthologue of pORF34 (VZV pORF32) is a phospho-
protein (Reddy et al., 1998) but could not conﬁrm phosphorylation
of the EHV-1 protein. Theoretically, glycosylation was also a
possibility and we used enzymatic digestion with PNGaseF and
EndoH to formally exclude that glycosylation is responsible for the
posttranslational modiﬁcation of the EHV-1 ORF34 protein.
Modiﬁcation of proteins by covalent attachment of ubiquitin or
ubiquitin-related polypeptides and the degradation of the conjugates
by the proteasome participate in the regulation of fundamental
cellular processes (Bregegere et al., 2006; Dye and Schulman, 2007;
Hershko and Ciechanover, 1998). It is therefore not surprising that
many pathogens have devoted a considerable part of their genomes
to the production of proteins that mimic, block or redirect the
activity of the ubiquitin–proteasome system in order to modify
the cellular environment and protect infected cells from the host's
immune attack. Our experiments with proteasome and E1 inhibitors
provided insights into the mechanism of pORF34 degradation.
Treatment with a proteasome inhibitor resulted in the inhibition of
pORF34 degradation in cells infected with rAb4_34-HA. Proteasome-
dependent protein degradation is usually contingent upon ubiquiti-
nation of proteins. Polyubiquitin is conjugated to target proteins
through a process involving E1 ubiquitin-activating enzymes, E2
ubiquitin conjugating enzymes, and E3 ubiquitin ligases (Hershko
and Ciechanover, 1998). It is worthwhile noting that the E1 inhibitor
controls the biological activity of the ubiquitin E1 and, hence, blocks
protein degradation (Teale et al., 2009; Yang et al., 2007). Therefore,
incubation of infected cells with E1 inhibitors inhibited pORF34
degradation in cells infected with rAb4_34-HA. On the other hand,
the size of pORF34 was reduced after treatment of infected cells with
E1 inhibitors, suggesting that the ORF34 protein is indeed modiﬁed
by addition of mono- or polyubiquitin. Interestingly, the kinetics of
pORF34 expression had shown protein stability until 10 h p.i. We
also noted that the apparent molecular mass of pORF34 of 28-kDa as
Fig. 8. Localization of p ORF34 in infected cells by immunoﬂuorescence and Western blot analysis of subcellular fractions. For immunoﬂuorescence, NBL6 cells were infected
with either parental rAb4, rAb4_34-HA or rAb4Δ34 virus. At 16 h p.i., cells were ﬁxed with 2% paraformaldehyde for 10 min and permeabilized with 0.1% saponin in PBS for
30 min. Monoclonal anti-HA and polyclonal Anti-ORF34 antibody were used as a primary antibody in (A) and (B), respectively, while Alexa Fluor 568 goat anti-mouse and
Alexa Fluor 488 goat anti-rabbit IgG were used as secondary antibodies. Coverslips were mounted in a VECTASHIEDs mounting medium with DAPI (Vector Laboratories) to
stain nuclei. Magniﬁcation: 40 , scale bar¼10 μm. (C) For cell fractionation, NBL6 cells were infected with rAb4_34-HA for 24 h or mock-infected, then cell lysates were
separated into cytoplasmic and nuclear fractions before immunoblot analysis. Identical amounts of the protein were separated in each lane of an SDS-12% polyacrylamide gel
and an anti-HA MAb was used for detection. pORF34 was not detected in the nuclear fraction (lane 2) but only the cytoplasmic fraction (lane 3). Prestained protein ladder
(Thermo Scientiﬁc) was used for determination of protein molecular masses.
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determined by immunoblot analysis is bigger than predicted based
on the primary sequence. Our ubiquitin pull-down experiments
suggest that the 28-kDa pORF34 moiety represents the viral protein
that is linked to a single ubiquitin molecule in the early stages of
infection, which may act as a signal for other ubiquitin ligases to
attach additional ubiquitin molecules at later times of infection. As a
target protein must be marked with at least four or more ubiquitin
molecules before it is recognized by the proteasome (Peters et al.,
1994; Thrower et al., 2000), the addition of multiple copies of
ubiquitin to pORF34 at later times of infection is likely necessary
for degradation of pORF34 by the 26S proteasome.
Another interesting ﬁnding was that pORF34 was stable until
10 h p.i. and was only degraded after that time. This ﬁnding led us
to examine whether expression of a late viral gene caused
degradation either directly or indirectly. We were able to conﬁrm
that treatment of infected cells with PAA, a drug that inhibits
expression of late viral proteins, resulted in enhanced stability of
pORF34. Our conclusion from the data is that pORF34 stability is
dependent on the time after infection and that pORF34 may only
be required at early times after infection or that its function at
later times after infection requires the protein be modiﬁed by
ubiquitination.
Immunoﬂuorescence analysis and fractionation studies of infected
cells indicated that the ORF34 protein is located in the cytoplasm of
infected cells. These ﬁndings are in agreement with previous results
for the VZV orthologue, which was reported to also be present in the
cytosol of infected cells (Reddy et al., 1998). Moreover, examination of
the replication properties of an EHV-1 lacking ORF34 (rAb4Δ34)
revealed a signiﬁcant reduction of one-step growth kinetics and virus
genome copies when compared to those of rAb4 and rAb4Δ34R. This
was true both for equine ﬁbroblast cells and equine PBMC at early but
not late times after infection.
Taking all data presented in this study into consideration, we
conclude that EHV-1 pORF34 (i) is expressed with early kinetics,
(ii) localizes to the cytosol of virus-infected cells, (iii) is stable
during early stages of infection but is degraded from its amino-
terminus through the ubiquitin/proteasome pathway, an activity
that is mediated directly or indirectly by late viral gene products,
and (iv) is required for efﬁcient virus growth in vitro at early stages
of infection. Further studies will be performed to address, which
late protein(s) of EHV-1 are involved in the degradation of pORF34
and which residues in the protein are required for this activity. The
role of the ORF34 gene product as well as the biological con-
sequences of its degradation in vivo will be investigated.
Materials and methods
Virus and cells
Mutant viruses were based on EHV-1 wild type strain Ab4. All
genetic manipulations and virus reconstitutions were done using
the infectious bacterial artiﬁcial chromosome (BAC) clone pAb4, in
which mini-F vector sequences also contain the gene expressing
the enhanced green ﬂuorescence protein (eGFP) instead of ORF71
that encodes gp2 (Rudolph et al., 2002). Rabbit kidney (RK13) cells
were propagated in modiﬁed Eagle's medium (MEM) (Biochrom)
supplemented with 5% fetal bovine serum (FBS) (Biochrom),
100 U/ml penicillin, and 100 μg/ml streptomycin (1% penicillin–
streptomycin). Equine dermal (NBL-6) cells were grown in Iscove's
modiﬁed Dulbecco's medium (IMDM; Invitrogen) supplemented
with 20% FBS and 1% penicillin–streptomycin. Peripheral blood
mononuclear cells (PBMC) were isolated from heparinized blood
collected from healthy horses by density gradient centrifugation
over Biocoll separating solution (density 1.077 g/ml) following the
manufacturer's instructions (Biochrom). After two washing steps,
cells were resuspended in RPMI 1640 supplemented with 10% FBS,
0.3 mg/ml glutamine, 100 μg/ml kanamycin, nonessential amino
acids (Biochrom) and 1% penicillin–streptomycin.
Fig. 9. Single-step growth kinetics and plaque sizes of rAb4Δ34 in comparison with
those of parental virus and rAb4_34R. (A) For analysis of plaques sizes, NBL6 cells
were infected with parental or mutant viruses and diameters of 50 plaques per
virus were measured after 3 days p.i. Plaque sizes are shown as mean plaque
diameters obtained in each experiment. Plaque sizes or rAb4 were set at 100%.
(B) For analysis of single-step growth kinetics, NBL6 cells were infected with
parental, rAb4Δ34 or rAb4Δ34R viruses. Signiﬁcant differences in the growth
properties of the viruses were identiﬁed at early (2–10 h p.i), but not late times of
infection (12–36 h p.i). Errors bars represent standard deviations.
Fig. 10. Replication properties of ORF34-negative virus in PBMC. Isolated equine
PBMC were infected with parental, rAb4Δ34 or rAb4Δ34R virus for 5 or 24 h. Virus
genome copies in PBMC were determined using qPCR targeting the EHV-1 IR6
(ORF67) gene. The equine β2M gene was used for normalization of virus to host
DNA copies. Means of viral genome copies normalized to 1106 β2M copies are
shown for the 5 and 24 h time point. Signiﬁcant differences (po0.05) are indicated
with an asterisk (*). All samples were run in triplicate and errors bars represent
standard deviations.
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Antibodies
Anti-peptide polyclonal pORF34-speciﬁc antibodies targeting
amino- or carboxy-terminal sequences were commercially gener-
ated (Genscript). The peptides were selected according to hydro-
philicity plots and their sequences are given in Table 1. The anti-HA
tag (6E2) mouse monoclonal antibody (MAb) and rabbit anti-β-actin
polyclonal antibody (pAb) were purchased from Cell Signaling
Technologies. MAb FK2 recognizing mono- and poly-ubiquitin was
obtained from Enzo Life Sciences. Mouse anti-EHV-1 gM MAb F6
(Ma et al., 2012; Rudolph and Osterrieder, 2002; Said et al., 2012)
and EHV-1 gB MAb 3F6 were described before (Allen and Yeargan,
1987; Neubauer et al., 1997). Anti-6X His epitope tag rabbit pAb was
purchased from Rockland. Alexa Fluor 568-conjugated goat anti-
mouse and Alex Fluor 488 goat anti-rabbit IgG were obtained from
Invitrogen, horseradish peroxidase-conjugated goat anti-rabbit and
goat anti-mouse antibodies purchased from Southern Biotech.
Plasmids
The EHV-1 ORF34 genewas ampliﬁed by PCR using primers P1 and
P2 (Table 2). The PCR products were digested with BamHI and EcoRI
and inserted into pcDNA3 (Invitrogen) resulting in recombinant
plasmid pcDNA_34. To construct pcDNA_34Kan, the kanamycin resis-
tance aphAI (kanR) gene was ampliﬁed from plasmid pEPkan-S by PCR
using primers P3 and P4 (Table 2). The ampliﬁed kanR gene was
cloned into a ClaI site located within ORF34. To generate pcDNA3
resulting in HA tag (YPYDVPDYA) expression at the C-terminus of
ORF34 (pcDNA_34-HA), the ORF34 gene was ampliﬁed by PCR from
Ab4 strain of EHV-1 using primers P1 and P5, the latter containing
sequences encoding the HA tag (Table 2). The 6XHis (pMT107)-tagged
ubiquitin expression plasmid has been previously described and was
kindly provided by Dr. Mathias Treier, EMBL, Heidelberg, Germany
(Treier et al., 1994).
BAC cloning and mutagenesis
For all genetic manipulations, Escherichia coli (E. coli) strain GS1783
harboring a temperature-sensitive Red recombination system and a
gene encoding the endonuclease I-SceI in its genome was used.
GS1783 cells containing pAb4 were maintained in Luria-Bertani (LB)
medium containing 30 mg/ml chloramphenicol. Deletion of ORF34 was
done by two-step Red recombination exactly as described before
(Tischer et al., 2006) and using PCR primers P8 and P9 (Table 2) that
allowed replacement of ORF34 by the aphAI (kanR) gene ampliﬁed
from plasmid pEPKan-S. Kanamycin-resistant colonies were isolated
and screened by PCR and restriction fragment length polymorphism
(RFLP) to detect E. coli cells harboring mutant clones. The ﬁnal
construct, pAb4Δ34, was obtained after removal of the aphAI gene.
To create pAb4 with HA tag sequences fused to the C-terminus of
ORF34 (pAb4_34-HA), we designed primers P10 and P11 (Table 2).
Finally, to reintroduce the authentic ORF34 in pAb4Δ34, a PCR
fragment containing EHV-1 ORF34 was cloned into pcDNA3 using
the restriction enzymes BamHI and EcoRI. Then kanR sequences were
cloned into the ClaI site, which is located at nucleotide position 184–
189 bp of ORF34. The revertant pAb4Δ34R was ﬁnalized by removal of
aphAI as described above using primers P12 and P13 (Table 2). PCR,
RFLP, and nucleotide sequencing using primers P6 and P7 (Table 2)
conﬁrmed the genotypes of the mutant and revertant pAb4 clones.
Reconstitution of recombinant viruses
To produce wild-type recombinant (r)Ab4, its derivative with a
deletion in ORF34 (rAb4Δ34) or a recombinant with an HA-tagged
ORF34 protein (rAb4_34-HA), RK13 cells were transfected with
2 μg of BAC DNA. Transfection was performed as previously des-
cribed (Rudolph et al., 2002).
Southern blotting
Southern blotting was used to conﬁrm the deletion of ORF34 in
pAb4Δ34. DNA of pAb4, pAb4Δ34 or pAb4Δ34R was digested with
Table 1
Synthetic pORF34 peptides for production of polyclonal antibodies.




Oligonucleotides used in this study.
Primer Product Sequence 50–30
Plasmid
P1 ORF34 attggatccgccaccatggattctccacgcggtatct






P6 Sequencing and tagagttgacgcttcctctt
P7 Southern blot aactaacaataaatacatac
Mutagenesis
P8 ORF34 deletion tgctctcgccgctcctgtgttagcgtatactgcccaagaataaaaaagcaaaaaataa ac aggatgacgacgataagtaggg
P9 acgtatataaactaaaaattgtttattttttgcttttttattcttgggcagtatacgctacaaccaattaaccaattctgattag






– Restriction enzyme sites are given in lower case bold letters; sequences in italics indicate additional bases, which are not present in the EHV-1 sequence.
– Underlined sequences indicate the template-binding region of the primers for PCR ampliﬁcation with pEPkan-s.
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XbaI and the fragments separated by 0.8% agarose gel electrophor-
esis. DNA was then transferred onto a positively charged nylon
membrane and hybridized using a digoxigenin-labeled ORF34
probe (Table 2) generated using the PCR DIG Probe Synthesis Kit
(Roche) as previously described (Osterrieder et al., 1996; Ziegler
et al., 2005). Hybridization was detected with an anti-digoxigenin
alkaline phosphatase (AP) antibody (Roche) and bound antibody
conjugates were visualized by chemiluminescence (CDP-Star,
Roche).
Immunoblotting and immunoprecipitation
For Western blot analysis, RK13 cells were seeded in 6-well
plates that were either mock-infected or infected with the various
viruses as indicated. Pellets of infected cells were resuspended in
radioimmunoprecipitation assay (RIPA) buffer (1 mM Tris, pH 7.4,
1% Triton X-100, 0.25% sodium deoxycholate, 5 M sodium chloride,
0.5 mM EDTA, 0.1% sodium dodecyl sulfate [SDS]) and a protease
inhibitor cocktail (Roche). Samples were mixed with sample
loading buffer (1 M Tris–HCl, pH 6.8, 0.8% SDS, 0.4% glycerol,
0.15% β-mercaptoethanol, 0.004% bromophenol blue), heated at
65 1C for 5 min, and subjected to SDS-10% polyacrylamide gel
electrophoresis (PAGE) exactly as described before (von Einem
et al., 2007). Expression of EHV-1 ORF34 protein (pORF34), and
glycoprotein M (gM) or cellular β-actin was detected with speciﬁc
antibodies and peroxidase conjugates listed earlier. Reactive bands
were visualized by enhanced chemiluminescence (ECL plus, GE
Healthcare). To examine pORF34 phosphorylation, cell lysates
were treated with λ-protein phosphatase (λ-PPase; New England
BioLabs) for 30 min at 30 1C before electrophoresis as described
(Ma et al., 2012; Said et al., 2012).
For immunoprecipitation, RK13 cells were ﬁrst transfected with the
6XHis (pMT107)-tagged ubiquitin expression plasmid for 24 h, then
infected with recombinant rAb4_34-HA. Pellets of transfected and
infected cells were resuspended in RIPA buffer and insoluble material
was removed by centrifugation at 2500g for 2 min. The supernatant
was incubated with either the anti-HA or anti-His MAb by shaking
gently at 4 1C overnight and the complexes were then precipitated
using protein G-agarose (Thermo Scientiﬁc) for 2 h. Immune com-
plexes were pelleted, washed in RIPA buffer 3 times, and heated at
65 1C for 5 min in loading buffer as described (Cohen and Seidel, 1995;
Feng et al., 2004). Reactive bands were visualized by detection using
ECL after SDS–PAGE and immunobloting with the reciprocal anti-
bodies. For precipitation of ubiquitinated pORF34 from cells infected
with rAb4 or rAb4_34HA virus, immunoprecipitation was performed
as described above using the anti-ubiquitin MAb or the anti-HA MAb,
respectively. After separation by SDS–PAGE, proteins were transferred
to PVDF membranes and visualized after immunobloting exactly as
described above using polyclonal anti-C-pORF34 antibodies.
Determination of the kinetic class of EHV-1 ORF34
To determine the kinetics of ORF34 expression, NBL-6 cells
were either mock-infected or infected with parental or rAb4_34-HA
viruses at a multiplicity of infection (m.o.i) of 5 in the presence of the
viral DNA synthesis inhibitor phosphonoacetic acid (PAA; Sigma) at a
concentration of 300 mg/ml, followed by incubation in fresh medium
containing PAA for 24 h (Honess and Watson, 1977; Said et al., 2012).
In order to differentiate between IE and E gene expression, NBL6 cells
were infected with rAb4_34-HA in the presence of cycloheximide
(CX; Sigma) at a concentration of 100 mg/ml medium, which is
known to inhibit viral protein synthesis in EHV-1 infected cells and
to allow accumulation of EHV-1 IE mRNA (Khattar et al., 1995; Said
et al., 2012). After 5 h, cells were extensively washed and incubated
with fresh medium containing the transcription inhibitor actinomy-
cin D (Act-D; Sigma) at 5 mg/ml. Translation of accumulated IE mRNA
is possible after wash-out of cycoheximide, while Act-D prevents
further transcription of mRNA. Cells were analyzed after each
treatment by immunoblot analysis.
Protein stability
In order to assess the effect of time after infection on pORF34
stability, RK13 cells were infected with rAb4_34-HA at an m.o.i. of
1 before samples were harvested at the indicated time points (1, 2,
3, 4, 5, 6, 8, 10, 12, 16 and 24 h p.i.) and analyzed using Western
blotting.
To determine whether pORF34 is modiﬁed post-translationally
by glycosylation, PNGaseF and EndoH treatment of infected-cell
lysates was performed as previously described (Seyboldt et al.,
2000). Cell lysates were suspended in digestion buffer and
digested with PNGaseF or EndoH as recommended by the manu-
facturer (BioLab). The reaction was mixed and incubated for 3 h at
37 1C. Separation of reaction products was examined by Western
blotting using anti-C-pORF34 antibody (Table 1).
To determine the degradation pathway of pORF34, rAb4_34-
HA-infected RK13 cells were incubated with medium containing
the proteasome inhibitor lactacystin at a ﬁnal concentration of
10 mM (Parkinson et al., 1999) added for 24 h at 37 1C after a 1 h
virus adsorption period. Infected cells were then collected and
lysed, and cell lysates analyzed by Western blot. To determine
whether proteasomal degradation of the protein was ubiquitin-
dependent, RK13 cells were transfected with the 6XHis (pMT107)-
tagged ubiquitin expression plasmid for 24 h and then infected
with rAb4_34-HA. Treatment with the proteasome inhibitor for
24 h followed, before infected cells were lysed, immunoprecipi-
tated, and subjected to Western blot analysis as described above.
Moreover, RK13 cells were also treated with the E1 inhibitor Pyr-
41 (Sigma) used at a ﬁnal concentration of 25 mM of for 8 h prior to
infection, exactly as previously described (Teale et al., 2009; Yang
et al., 2007). Following pre-treatment, inhibitors were removed by
washing the cells with PBS and cells were infected with rAb4_34-
HA virus (m.o.i.¼5). After 1 h of infection, cells were treated again
with Pyr-41 for 24 h, then the treated cells were harvested and
analyzed by Western blotting.
Indirect immunoﬂuorescence (IF) and cell fractionation
To evaluate intracellular expression of pORF34 in infected cells
by indirect IF, NBL6 cells were grown on coverslips and infected
with either parental, rAb4_34-HA or rAb4Δ34 viruses at an m.o.i of
0.1. At 16 h p.i., cells were ﬁxed with 2% paraformaldehyde in PBS
for 10 min and washed with PBS 3 times, followed by permeabi-
lization with 0.1% saponin for 30 min. After blocking with 2%
bovine serum albumin for 1 h, cells were incubated with anti-HA
mouse MAb (1/500) or anti-ORF34 pAb (1/200) for 1 h at RT. After
3 washing steps with PBS, cells were incubated with secondary
Alexa Fluor 568 goat anti-mouse or Alexa Fluor 488 goat anti-
rabbit (1/5000) IgG for 1 h at RT exactly as described previously
(Ahn et al., 2011; Ma et al., 2012). Finally, after 3 washing steps,
Vectashields mounting medium with DAPI (Vector Laboratories)
was added to cells and the coverslips were inspected under a Zeiss
Axio Imager M1 microscope (Zeiss, Germany).
Cells were separated into cytoplasmic and nuclear fractions by
the following procedure (Ahn et al., 2011; de Mendez et al., 1994).
NBL6 cells were infected with rAb4_34-HA and washed at 24 h p.i
with ice-cold PBS. Cells were then scraped off of the surface,
centrifuged and pellets resuspended in ice-cold buffer (10 mM
HEPES, pH 7.9; 10 mMMgCl2; 10 mM KCl; 0.5 mM DTT). Cells were
disrupted and centrifuged at 300g for 5 min at 4 1C to pellet the
nuclei. The supernatant was saved as the cytoplasmic fraction.
Nuclear pellets were disrupted with RIPA buffer and centrifuged at
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3000g for 15 min at 4 1C to pellet insoluble debris. Cytoplasmic
and nuclear fractions were analyzed by Western blotting.
Virus growth kinetics, plaque size measurements and quantitative
PCR (qPCR)
Plaque sizes and growth kinetics of rAb4Δ34 were determined
and compared to parental virus (von Einem et al., 2007). For
plaque size measurements, conﬂuent monolayers of NBL6 cells
were infected with mutant and parental virus and plaque sizes
were determined by IF at 3 days p.i. and analyzed using ImageJ
software (http://rsb.info.nih.gov/ij/). For single-step growth
kinetics, NBL6 cells were infected with mutant and parental
viruses at an m.o.i. of 3. Single-step growth curves were deter-
mined in three independent experiments by titrating cell culture
supernatants or from cell lysates generated by freeze–thawing
twice (cell-associated titers) at the indicated times p.i. (Rudolph
et al., 2002).
To determine whether the deletion of ORF34 would affect virus
replication in equine PBMC, quantitative (q) PCR was used. Equine
PBMC (2107 cells) were infected either with parental rAb4,
rAb4Δ34 or rAb4_34-HA viruses at an m.o.i of 0.5. After EHV-1
infection, cells were treated with citrate buffer (pH 3.0) to
inactivate remaining extracellular virus (Mettenleiter, 1989;
van Der Meulen et al., 2000) and fresh culture media was added
before cells were incubated at 37 1C for either 5 or 24 h. For qPCR,
PBMC were washed three times with PBS to remove viruses in the
supernatant, and genomic DNA was extracted by using an RTPs
DNA/RNA Virus Mini Kit (Stratec AG). qPCR was then performed by
using the 7500-Fast real-time qPCR system (Applied Biosystems)
in a total volume of 20 μl (Goodman et al., 2007). The horse
β2-microglobulin (β2M) gene was used to normalize virus to host
genome copies using primers and an MGB probe as described
earlier (Goodman et al., 2006, 2007). pAb4 was used as the virus
standard and a BAC clone of equine chromosome containing the
β2M gene (kindly provided by Dr D. Antczak, Cornell University,
NY, USA) was used for host genome copy quantiﬁcation. The
experiment was performed in three independent replicates and
each sample was also tested in duplicate for each experiment.
Statistical analysis
Using Microsoft Excel, Student's t-test for paired data was used
to test for signiﬁcant differences. Data given are means and bars
show standard deviations.
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